| 摘要 |
Paroxetine hydrochloride is prepared by subjecting (-)-trans-1-benzyl-4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl) piperidine hydrochloride to catalytic hydrogenation in the presence of a noble metal catalyst in a solvent system consisting of either a mixture of propan-2-o1 and a co-solvent, such as acetic acid, or a solvent other than propan-2-o1, preferably ethanol or methanol, optionally with a co-solvent such as water or acetic acid. Use of this solvent system reduces the amount of residual starting material in the paroxetine hydrochloride product. |
